Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 31;36(21):e153.
doi: 10.3346/jkms.2021.36.e153.

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea

Yun Woo Lee  1 , So Yun Lim  1 , Ji Hyang Lee  2 , Joon Seo Lim  3 , Miseo Kim  4 , Seonhee Kwon  4 , Jiyeon Joo  4 , Sun Hee Kwak  4 , Eun Ok Kim  4 , Jiwon Jung  1   4 , Hyouk Soo Kwon  2 , Tae Bum Kim  2 , Sung Han Kim  1   4 , Seongman Bae  5
Affiliations

Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea

Yun Woo Lee et al. J Korean Med Sci. .

Abstract

We conducted a prospective, mobile-based survey on the self-reported adverse reactions in healthcare workers (HCWs) who received both doses of the BNT162b2 mRNA vaccine. Of the 342 HCWs who completed the two-dose vaccination, 265 (77.5%) responded to the survey at least once. Overall, the rates of adverse reactions were higher after the second dose compared with the first dose (89.1% vs. 80.1%, P = 0.006). The most common systemic reactions were muscle ache (69.1%), fatigue (65.7%), headache (48.7%), chills (44.2%), and fever (32.1%), and were notably more common after the second dose vaccine as well. We also noted a sex difference in which the frequency of adverse reactions after the second dose of the vaccine was significantly higher in females, which was not observed after the first dose. The rates of adverse reactions were lower in older age groups, and the rates and severities of the adverse reactions decreased during the 3-day period following vaccination.

Keywords: Adverse Reaction; BNT162b2; COVID-19; Vaccination.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. Adverse reactions reported within 3 days following dose 1 and dose 2 of the BNT162b2 vaccine. The numbers indicate the rates (%) of each adverse reaction. Data on the frequency of adverse reactions following the first dose of the ChAdOx1 nCoV-19 and the BNT162b2 vaccines were adopted from our previous work.
*P < 0.05, ***P < 0.001.
See this image and copyright information in PMC

References

    1. Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021 doi: 10.1001/jama.2021.5374. Forthcoming. - DOI - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. - PMC - PubMed
    1. Walsh EE, Frenck RW, Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. - PMC - PubMed
    1. Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17):e115. - PMC - PubMed
    1. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00224-3. Forthcoming. - DOI - PMC - PubMed